ABPEPserver: a web application for documentation and analysis of substitutants.
Cancer
Codon reassignment
Immunotherapy
Substitutants
Translation
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
03 Jun 2023
03 Jun 2023
Historique:
received:
04
05
2022
accepted:
16
05
2023
medline:
5
6
2023
pubmed:
4
6
2023
entrez:
3
6
2023
Statut:
epublish
Résumé
Cancer immunotherapy is implemented by identifying antigens that are presented on the cell surface of cancer cells and illicit T-cell response (Schumacher and Schreiber, Science 348:69-74, 2015; Waldman et al., Nat Rev Immunol 20:651-668, 2020; Zhang et al., Front Immunol 12:672,356, 2021b). Classical candidates of such antigens are the peptides resulting from genetic alterations and are named "neoantigen" (Schumacher and Schreiber, Science 348:69-74, 2015). Neoantigens have been widely catalogued across several human cancer types (Tan et al., Database (Oxford) 2020;2020b; Vigneron et al., Cancer Immun 13:15, 2013; Yi et al., iScience 24:103,107, 2021; Zhang et al., BMC Bioinformatics 22:40, 2021a). Recently, a new class of inducible antigens has been identified, namely Substitutants, that are produced as a result of aberrant protein translation (Pataskar et al., Nature 603:721-727, 2022). MAIN: Catalogues of Substitutant expression across human cancer types, their specificity and association to gene expression signatures remain elusive for the scientific community's access. As a solution, we present ABPEPserver, an online database and analytical platform that can visualize a large-scale tumour proteomics analysis of Substitutant expression across eight tumour types sourced from the CPTAC database (Edwards et al., J Proteome Res 14:2707-2713, 2015). Functionally, ABPEPserver offers the analysis of gene-association signatures of Substitutant peptides, a comparison of enrichment between tumour and tumour-adjacent normal tissues, and a list of peptides that serve as candidates for immunotherapy design. ABPEPserver will significantly enhance the exploration of aberrant protein production in human cancer, as exemplified in a case study. ABPEPserver is designed on an R SHINY platform to catalogue Substitutant peptides in human cancer. The application is available at https://rhpc.nki.nl/sites/shiny/ABPEP/ . The code is available under GNU General public license from GitHub ( https://github.com/jasminesmn/ABPEPserver ).
Sections du résumé
BACKGROUND
BACKGROUND
Cancer immunotherapy is implemented by identifying antigens that are presented on the cell surface of cancer cells and illicit T-cell response (Schumacher and Schreiber, Science 348:69-74, 2015; Waldman et al., Nat Rev Immunol 20:651-668, 2020; Zhang et al., Front Immunol 12:672,356, 2021b). Classical candidates of such antigens are the peptides resulting from genetic alterations and are named "neoantigen" (Schumacher and Schreiber, Science 348:69-74, 2015). Neoantigens have been widely catalogued across several human cancer types (Tan et al., Database (Oxford) 2020;2020b; Vigneron et al., Cancer Immun 13:15, 2013; Yi et al., iScience 24:103,107, 2021; Zhang et al., BMC Bioinformatics 22:40, 2021a). Recently, a new class of inducible antigens has been identified, namely Substitutants, that are produced as a result of aberrant protein translation (Pataskar et al., Nature 603:721-727, 2022). MAIN: Catalogues of Substitutant expression across human cancer types, their specificity and association to gene expression signatures remain elusive for the scientific community's access. As a solution, we present ABPEPserver, an online database and analytical platform that can visualize a large-scale tumour proteomics analysis of Substitutant expression across eight tumour types sourced from the CPTAC database (Edwards et al., J Proteome Res 14:2707-2713, 2015). Functionally, ABPEPserver offers the analysis of gene-association signatures of Substitutant peptides, a comparison of enrichment between tumour and tumour-adjacent normal tissues, and a list of peptides that serve as candidates for immunotherapy design. ABPEPserver will significantly enhance the exploration of aberrant protein production in human cancer, as exemplified in a case study.
CONCLUSION
CONCLUSIONS
ABPEPserver is designed on an R SHINY platform to catalogue Substitutant peptides in human cancer. The application is available at https://rhpc.nki.nl/sites/shiny/ABPEP/ . The code is available under GNU General public license from GitHub ( https://github.com/jasminesmn/ABPEPserver ).
Identifiants
pubmed: 37270525
doi: 10.1186/s12885-023-10970-8
pii: 10.1186/s12885-023-10970-8
pmc: PMC10239192
doi:
Substances chimiques
Peptides
0
Antigens
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
502Subventions
Organisme : KWF Kankerbestrijding
ID : 13647
Organisme : FP7 Ideas: European Research Council
ID : 832844
Informations de copyright
© 2023. The Author(s).
Références
Nat Methods. 2020 Sep;17(9):869-870
pubmed: 32669682
Nature. 2022 Mar;603(7902):721-727
pubmed: 35264796
Cancer Cell. 2021 Apr 12;39(4):509-528.e20
pubmed: 33577785
Cell. 2021 Aug 5;184(16):4348-4371.e40
pubmed: 34358469
Cancer Immun. 2013 Jul 15;13:15
pubmed: 23882160
BMC Bioinformatics. 2021 Apr 14;22(Suppl 8):40
pubmed: 33849445
Bioinformatics. 2016 Feb 15;32(4):511-7
pubmed: 26515819
Biomed Pharmacother. 2020 Apr;124:109821
pubmed: 31962285
Front Immunol. 2019 Feb 08;10:168
pubmed: 30800125
Nat Rev Immunol. 2020 Nov;20(11):651-668
pubmed: 32433532
Cell. 2021 Sep 16;184(19):5031-5052.e26
pubmed: 34534465
iScience. 2021 Sep 09;24(10):103107
pubmed: 34622160
Cell Rep Med. 2020 Apr 21;1(1):
pubmed: 32529193
Nat Biotechnol. 2022 Feb;40(2):175-188
pubmed: 34635837
Front Immunol. 2021 Apr 16;12:672356
pubmed: 33936118
Cancer Cell. 2021 Mar 8;39(3):361-379.e16
pubmed: 33417831
Cell. 2019 Oct 3;179(2):561-577.e22
pubmed: 31585088
Cell. 2019 Oct 31;179(4):964-983.e31
pubmed: 31675502
Cell. 2020 Feb 20;180(4):729-748.e26
pubmed: 32059776
J Proteome Res. 2015 Jun 5;14(6):2707-13
pubmed: 25873244
Nat Rev Cancer. 2021 Jun;21(6):345-359
pubmed: 33837297
Science. 2015 Apr 3;348(6230):69-74
pubmed: 25838375
Database (Oxford). 2020 Jan 1;2020:
pubmed: 32090262